GO:0098735 positive regulation of the force of heart contraction: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0098735 describes any biological process that increases the force of heart muscle contraction, a critical determinant of cardiac output and stroke volume [2, 6].
• The term encompasses both acute inotropic modulation (e.g., adrenergic and dopaminergic signaling) and longer-term structural/functional adaptations of the myocardium [2, 3, 6].
• Key molecular players include beta-adrenergic receptors, dopamine receptors, ion channels, myosin regulatory proteins, and neuropeptides such as VIP [2, 3, 6, 7, 8].
• Dysregulation of positive inotropic mechanisms is central to heart failure, arrhythmias, and cardiomyopathies, making it a major therapeutic target.
• Research into this process uses knockout, knock-in, and overexpression models, combined with physiological measurements, imaging, and omics approaches [1, 5].
• CRISPR-based editing enables precise dissection of gene function in cardiac contractility, from point mutations to tagged reporters [1, 5].
Description
Positive regulation of the force of heart contraction (GO:0098735) is a biological process that increases the force of heart muscle contraction. This process is fundamental to the heart's ability to adapt cardiac output to physiological demand, such as during exercise or stress [2, 6]. At the molecular level, it involves a complex interplay of receptor signaling, ion flux, and sarcomeric protein regulation that ultimately enhances the strength of each heartbeat [2, 3, 7]. Understanding this process is essential for researchers studying cardiac physiology, heart failure, and therapeutic strategies aimed at modulating contractility. The term is distinct from general heart contraction, focusing specifically on the upregulation of contractile force, which can occur through acute inotropic mechanisms or chronic remodeling [2, 6]. This article synthesizes current knowledge on the mechanisms, genes, and research methods associated with GO:0098735, drawing on authoritative QuickGO data and published literature.
positive regulation of the force of heart contraction At A Glance
| GO ID | GO:0098735 |
|---|---|
| GO term | positive regulation of the force of heart contraction |
| Ontology | biological_process |
| Synonym | none |
| Major function | Increases the force of heart muscle contraction |
| Related processes | Adrenergic signaling, calcium handling, sarcomere regulation |
| Key regulators | Beta-adrenergic receptors, dopamine receptors, ion channels, myosin |
| Disease relevance | Heart failure, arrhythmias, cardiomyopathies |
What Is GO:0098735?
GO:0098735, positive regulation of the force of heart contraction, is defined as any process that increases the force of heart muscle contraction. This encompasses signaling pathways, ion channel modulation, and sarcomeric changes that enhance the strength of cardiac muscle contraction, leading to increased stroke volume and cardiac output [2, 6].
Why Is positive regulation of the force of heart contraction Important in Cell Biology?
Positive regulation of the force of heart contraction is vital for maintaining cardiac output and responding to increased metabolic demands. Its dysregulation contributes to major cardiovascular diseases, including heart failure and arrhythmias, where impaired contractility or excessive inotropic stimulation can be detrimental. Understanding the molecular underpinnings of this process is crucial for developing targeted therapies that can enhance contractility when needed or prevent pathological overstimulation [2, 3, 6].
• Essential for physiological adaptation to exercise and stress.
• Central to the pathophysiology of heart failure, where contractility is often compromised.
• Target of widely used inotropic drugs such as dobutamine and dopamine [3, 6].
• Involved in arrhythmogenesis when overstimulated.
• Modulated by neuropeptides like VIP, affecting coronary blood flow and contractility.
• Regulated by ion channels, including mechanically activated channels in myocardial delamination.
• Myosin regulatory pathways are key determinants of contractile force.
• Dopamine and its receptors influence cardiac contractility in health and disease.
• Satellite cell dysfunction in neuromuscular disorders can indirectly affect cardiac muscle.
• Provides targets for gene therapy and CRISPR-based interventions [1, 5].
What Happens During positive regulation of the force of heart contraction?
Receptor-Mediated Signaling
In simple terms: Hormones and neurotransmitters bind to receptors on heart cells, triggering a cascade that makes the heart beat stronger.
Positive regulation of heart contraction force often begins with the binding of catecholamines (e.g., norepinephrine, epinephrine) to beta-adrenergic receptors on cardiomyocytes. This activates Gs proteins, adenylyl cyclase, and cyclic AMP (cAMP), leading to protein kinase A (PKA) activation [2, 6]. PKA phosphorylates key targets such as L-type calcium channels, ryanodine receptors, and phospholamban, enhancing calcium influx and release, which increases contractile force. Dopamine, acting through D1-like receptors, can also exert positive inotropic effects in the heart. Additionally, vasoactive intestinal peptide (VIP) has been shown to increase cardiac contractility and coronary blood flow.
Calcium Handling and Excitation-Contraction Coupling
In simple terms: Calcium ions are the direct trigger for heart muscle contraction; more calcium means a stronger beat.
The force of heart contraction is directly proportional to the amount of calcium available during systole. Positive regulation involves increased calcium entry through L-type calcium channels and enhanced calcium-induced calcium release from the sarcoplasmic reticulum via ryanodine receptors (RyR2). Phosphorylation of phospholamban by PKA relieves inhibition of SERCA2a, increasing calcium reuptake into the sarcoplasmic reticulum and thereby augmenting calcium load for subsequent beats. This calcium handling is a central mechanism for the force-frequency relationship, where higher heart rates lead to increased contractility.
Sarcomeric and Myosin Regulation
In simple terms: The heart's molecular motors, myosin, can be tuned to generate more force.
At the sarcomere level, positive regulation of contraction force involves modulation of myosin heavy chain and regulatory light chain phosphorylation. For example, myosin regulatory light chain phosphorylation by myosin light chain kinase can enhance calcium sensitivity of the contractile apparatus. Recent studies have resolved zone-specific regulation of cardiac myosin, highlighting how different regions of the myosin molecule contribute to force generation. Additionally, mechanically activated channels and signaling pathways, such as snai1b, coordinate myocardial delamination and trabeculation, which are essential for developing a contractile heart.
Neurohumoral and Endothelial Modulation
In simple terms: The heart's contractility is also influenced by signals from blood vessels and nerves.
Vasoactive intestinal peptide (VIP) is a neuropeptide that exerts positive inotropic and chronotropic effects on the heart, in addition to vasodilation. Dopamine, beyond its role as a neurotransmitter, can directly affect cardiac contractility through receptors on cardiomyocytes. The endothelium and vascular smooth muscle also release factors that modulate cardiac performance, and ion channels in these cells contribute to the regulation of vasomotion, indirectly affecting cardiac load and contractility. These neurohumoral mechanisms integrate systemic demands with cardiac output.
Key Genes Involved in GO:0098735 positive regulation of the force of heart contraction
The following genes and proteins are key players in the positive regulation of the force of heart contraction, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor; mediates catecholamine-induced increases in contractility | Target for heart failure therapy; knockout models show altered inotropic response |
| ADRB2 | Beta-2 adrenergic receptor; modulates contractility and relaxation | Polymorphisms linked to heart failure outcomes |
| DRD1 | Dopamine receptor D1; mediates dopamine-induced positive inotropy | Potential target for inotropic support |
| DRD2 | Dopamine receptor D2; modulates cardiac function | Investigated in heart failure and hypertension |
| CACNA1C | L-type calcium channel alpha-1C subunit; controls calcium influx | Mutations cause Timothy syndrome and arrhythmias |
| RYR2 | Ryanodine receptor 2; calcium release channel of sarcoplasmic reticulum | Mutations linked to catecholaminergic polymorphic ventricular tachycardia |
| PLN | Phospholamban; regulates SERCA2a activity | Phosphorylation enhances calcium reuptake and contractility |
| MYH7 | Beta-myosin heavy chain; major sarcomeric motor protein | Mutations cause hypertrophic and dilated cardiomyopathy |
| MYL2 | Myosin regulatory light chain; modulates calcium sensitivity | Phosphorylation regulates force generation |
| MYL3 | Myosin essential light chain; structural and regulatory roles | Mutations associated with cardiomyopathy |
| TNNT2 | Cardiac troponin T; regulates actin-myosin interaction | Mutations cause familial hypertrophic cardiomyopathy |
| ACTC1 | Cardiac actin; core component of thin filament | Mutations linked to dilated cardiomyopathy |
| VIP | Vasoactive intestinal peptide; positive inotrope and vasodilator | Cardiovascular effects in heart failure |
| SNAI1B | Mechanically activated transcription factor; coordinates myocardial delamination | Essential for trabeculation and contractile development |
| SCN5A | Voltage-gated sodium channel; initiates action potential | Mutations cause Brugada syndrome and arrhythmias |
| KCNQ1 | Potassium channel; repolarization | Mutations cause long QT syndrome |
| ATP2A2 | SERCA2a; calcium pump of sarcoplasmic reticulum | Overexpression improves contractility in heart failure models |
How Is positive regulation of the force of heart contraction Regulated?
The positive regulation of the force of heart contraction is tightly regulated by the autonomic nervous system, circulating hormones, and local factors. Beta-adrenergic signaling is the primary acute regulator, but chronic stimulation leads to desensitization and downregulation of receptors, as seen in heart failure. Dopamine and VIP provide additional modulatory inputs [3, 8]. At the cellular level, calcium handling proteins and sarcomeric regulators are subject to phosphorylation and other post-translational modifications that fine-tune contractility [2, 7]. Mechanically activated pathways, such as those involving SNAI1B, link hemodynamic forces to developmental and adaptive responses.
positive regulation of the force of heart contraction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADRB1 | Heart failure; altered inotropic response | Knockout mouse; overexpression in cardiomyocytes |
| CACNA1C | Timothy syndrome; arrhythmias | Point mutation knock-in mouse; iPSC-derived cardiomyocytes |
| RYR2 | Catecholaminergic polymorphic ventricular tachycardia | Knock-in mouse with RYR2 mutation; CRISPR-edited hiPSCs |
| MYH7 | Hypertrophic cardiomyopathy | Knock-in mouse; patient-derived iPSCs |
| SCN5A | Brugada syndrome; arrhythmias | Knockout and knock-in models; heterologous expression |
Heart Failure
In heart failure, the heart's ability to increase contractile force is impaired. Chronic overstimulation of beta-adrenergic receptors leads to receptor desensitization and downregulation, reducing inotropic reserve. Alterations in calcium handling, including decreased SERCA2a activity and increased phospholamban inhibition, contribute to systolic dysfunction. Therapies that modulate these pathways, such as beta-blockers, aim to restore balance and improve outcomes.
Arrhythmias and Channelopathies
Mutations in ion channels that regulate contractility can cause arrhythmias. For example, gain-of-function mutations in CACNA1C (L-type calcium channel) lead to Timothy syndrome, characterized by arrhythmias and impaired contractility. Similarly, mutations in RYR2 cause catecholaminergic polymorphic ventricular tachycardia, where excessive calcium release triggers arrhythmias. SCN5A and KCNQ1 mutations affect action potential duration and can lead to Brugada syndrome and long QT syndrome, respectively.
Cardiomyopathies
Cardiomyopathies often involve mutations in sarcomeric proteins that alter contractile force. Mutations in MYH7, MYL2, MYL3, TNNT2, and ACTC1 are associated with hypertrophic or dilated cardiomyopathy. These mutations can affect myosin motor function, calcium sensitivity, or force transmission, leading to impaired cardiac performance. Understanding these molecular defects is crucial for developing targeted therapies.
Neuromuscular Disorders with Cardiac Involvement
Muscle satellite cell dysfunction in neuromuscular disorders can indirectly affect cardiac muscle, as satellite cells are essential for muscle regeneration and repair. Although primarily studied in skeletal muscle, similar mechanisms may contribute to cardiac pathology in conditions like muscular dystrophies.
From positive regulation of the force of heart contraction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ADRB1 affect basal and stimulated contractility? | ADRB1 knockout mouse |
| How does a specific CACNA1C mutation alter calcium handling? | Point mutation knock-in mouse or hiPSC-derived cardiomyocytes |
| Can overexpression of SERCA2a rescue heart failure? | AAV-mediated overexpression in rodent heart failure models |
| What is the role of MYL2 phosphorylation in force generation? | Phospho-mimetic knock-in mouse |
| How does SNAI1B coordinate myocardial delamination? | Zebrafish knockout and transgenic reporter lines |
| Does VIP infusion improve cardiac function in heart failure? | Large animal model with VIP infusion and hemodynamic monitoring |
How to Study the positive regulation of the force of heart contraction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Echocardiography | Cardiac function in vivo (ejection fraction, fractional shortening) | Assessing inotropic effects in animal models |
| Pressure-volume loop analysis | Load-dependent and load-independent contractility | Hemodynamic studies in large animals |
| Calcium imaging | Intracellular calcium transients and sparks | Evaluating calcium handling in cardiomyocytes |
| Phosphoproteomics | Global phosphorylation changes | Identifying signaling pathways in inotropy |
| RNA-seq | Transcriptional changes | Discovering gene expression programs in heart failure |
| CRISPR knockout screens | Gene function loss-of-function | Identifying novel regulators of contractility |
| Traction force microscopy | Force generated by single cardiomyocytes | Measuring contractility at cellular level |
Physiological Measurements
Contractile force can be measured ex vivo using isolated cardiomyocytes (e.g., edge detection, traction force microscopy) or in vivo using echocardiography, pressure-volume loops, and cardiac MRI. These methods assess ejection fraction, fractional shortening, and dP/dt, providing direct readouts of inotropic state [2, 6].
Calcium Imaging
Calcium transients and sparks are measured using fluorescent indicators (e.g., Fura-2, Fluo-4) in isolated cardiomyocytes or intact hearts. This reveals alterations in calcium handling that underlie changes in contractility.
Molecular and Omics Approaches
RNA-seq, proteomics, and phosphoproteomics can identify global changes in gene expression and post-translational modifications associated with positive inotropy. For example, phosphoproteomics can reveal PKA targets following beta-adrenergic stimulation [2, 7].
Genetic and CRISPR Screens
CRISPR knockout and activation screens in cardiomyocytes or animal models can identify novel regulators of contractility. Libraries targeting kinases, phosphatases, and ion channels have been used to uncover modulators of cardiac function [1, 5].
How CRISPR Can Be Used to Study GO:0098735 positive regulation of the force of heart contraction
Knockout
CRISPR knockout of candidate genes (e.g., ADRB1, DRD1) in cardiomyocytes or animal models can determine their necessity for positive regulation of contractile force. For example, ADRB1 knockout mice show blunted inotropic responses to catecholamines.
Point Mutation
Introducing disease-associated point mutations (e.g., in CACNA1C or RYR2) using CRISPR base editing or homology-directed repair allows precise modeling of channelopathies and cardiomyopathies, revealing how specific residues affect contractility.
Knock-in
Knock-in of reporter genes (e.g., fluorescent tags on MYH7) or phospho-mimetic mutations (e.g., MYL2) enables real-time visualization of sarcomeric dynamics and assessment of phosphorylation effects on force.
Overexpression
CRISPR activation (CRISPRa) or viral overexpression of genes like ATP2A2 (SERCA2a) can enhance contractility and rescue heart failure phenotypes in preclinical models.
How EDITGENE Supports positive regulation of the force of heart contraction Research
Researchers studying positive regulation of the force of heart contraction-related genes often need to determine whether a candidate gene is causally involved in modulating contractility. This requires precise genetic models that can isolate the gene's function in cardiac cells. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such discoveries, from knockout to knock-in and overexpression models, coupled with library screening and bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of the force of heart contraction research.
Frequently Asked Questions About positive regulation of the force of heart contraction
What is GO:0098735?
GO:0098735 is the Gene Ontology term for positive regulation of the force of heart contraction, defined as any process that increases the force of heart muscle contraction.
What genes are involved in positive regulation of the force of heart contraction?
Key genes include ADRB1, ADRB2, DRD1, DRD2, CACNA1C, RYR2, PLN, MYH7, MYL2, MYL3, TNNT2, ACTC1, VIP, SNAI1B, SCN5A, KCNQ1, and ATP2A2 [2, 3, 5, 6, 7, 8].
How is the force of heart contraction increased?
It is increased through receptor-mediated signaling (e.g., beta-adrenergic), enhanced calcium handling, and sarcomeric regulation [2, 6].
What diseases are associated with abnormal positive regulation of heart contraction force?
Heart failure, arrhythmias, channelopathies, and cardiomyopathies [2, 4, 6, 7].
What research methods are used to study this process?
Methods include echocardiography, pressure-volume loops, calcium imaging, phosphoproteomics, RNA-seq, and CRISPR screens [2, 6, 7].
How can CRISPR help study positive regulation of heart contraction?
CRISPR enables knockout, point mutation, knock-in, and overexpression models to dissect gene function in contractility [1, 5].
What is the role of dopamine in heart contractility?
Dopamine can increase cardiac contractility through D1-like receptors, and its effects are studied in heart failure.
What is the force-frequency relationship?
It is the phenomenon where increased heart rate leads to increased contractile force, mediated by calcium handling and adrenergic signaling.
Which myosin genes are important for contractile force?
MYH7, MYL2, and MYL3 are critical for myosin motor function and force generation.
How does VIP affect the heart?
VIP increases cardiac contractility and coronary blood flow, acting as a positive inotrope and vasodilator.
Conclusion
Positive regulation of the force of heart contraction (GO:0098735) is a fundamental biological process that integrates neurohumoral signals, calcium handling, and sarcomeric function to enhance cardiac output. Its dysregulation underlies major cardiovascular diseases, making it a prime target for therapeutic intervention. Advances in CRISPR-based gene editing and multi-omics approaches are accelerating the discovery of novel regulators and disease mechanisms. EDITGENE offers comprehensive services to support researchers in this field, from custom knockout models to high-throughput screens.
References
- 1. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 2. Ross J Jr. 1998. Adrenergic regulation of the force-frequency effect.. Basic Res Cardiol 93 Suppl 1:95-101 PMID: 9833136
- 3. Neumann J et al.. 2023. Role of Dopamine in the Heart in Health and Disease.. Int J Mol Sci 24(5) PMID: 36902474
- 4. Kim DH et al.. 2023. Vasomotion in human arteries and their regulations based on ion channel regulations: 10 years study.. J Cell Physiol 238(9):2076-2089 PMID: 37672477
- 5. Wang J et al.. 2025. Mechanically activated snai1b coordinates the initiation of myocardial delamination for trabeculation.. Nat Commun 16(1):8363 PMID: 40993149
- 6. Brodde OE et al.. 1992. Receptor systems affecting force of contraction in the human heart and their alterations in chronic heart failure.. J Heart Lung Transplant 11(4 Pt 2):S164-74 PMID: 1355362
- 7. Nelson SR. 2025. Resolving zone-specific regulation of cardiac myosin.. J Gen Physiol 157(6) PMID: 40876855
- 8. Henning RJ et al.. 2001. Vasoactive intestinal peptide: cardiovascular effects.. Cardiovasc Res 49(1):27-37 PMID: 11121793
